Pro Medicus, Ltd. · ASX:PME
Pro Medicus — Shareholder Meeting (November 2012)
33 slides from Pro Medicus's shareholder meeting presentation, Nov 20, 2012
Slide 1: Annual General Meeting November 2012
For personal use only Annual General Meeting November 2012
Slide 2: Chairman's Address to AGM: Welcome and Introduction
PRO MEDICUS LIMITED Chairman’s Address to AGM 20 November 2012 WELCOME AND INTRODUCTION For personal use only Ladies and Gentlemen, On behalf of my fellow Directors I would like to welcome you to the Annual General Meeting of Pro Medicus Limited and thank you for taking the time to be with us. My na
Slide 3: Chairman's Report
CHAIRMAN’S REPORT Overview The financial results for the 2012 financial year were a considerable improvement on the previous year but are not at a level with which the Board is satisfied. We are still For personal use only on a long term journey and the Company is unlikely to reach its full potentia
Slide 4: Chairman's Report: Dividends and Remuneration
our confidence in the long term future of the Company. The sale of the Amira business has provided the Company with additional financial capacity and the Board expects to continue to pay dividends in the foreseeable future. Executive Directors Remuneration For personal use only As discussed at last
Slide 5: Chairman's Address AGM 2012
Chairman’s Address For personal use only AGM 2012 • Introduction & Welcome • Market overview & Update • Sale of Amira • Dividend Policy • Other matters
Slide 6: CEO Address
For personal use only Annual General Meeting CEO Address
Slide 7: Year in Review
For personal use only Year in Review • Company turnaround commenced • Cost containment in US • Sale of Amira for €12.1M • New technology platform (Coral) released in August • Resumption of dividends (1.5c ff) • Cash reserves over $5M plus proceeds from Amira • Company remains debt free
Slide 8: Product Update
For personal use only Annual General Meeting Product Update
Slide 9: "Coral" – everything is new!
“Coral” – everything is new ! For personal use only
Slide 10: Milestones – New Technology Platform Coral
Milestones – New Technology Platform “Coral” For personal use only • Commercially released August 2012 • Implemented in a comprehensive radiology site • Fully integrated with Visage technology • Early sales positive - include multiple new clients • Larger installations scheduled for early CY-Q1 • Ro
Slide 11: Milestones - Visage 7.0
Milestones - Visage For personal use only • Visage 7.0 - leading edge technology • Well positioned in growing 3D-PACS market. • Highly modular/scalable solution: – Leading edge 3D PACS – Enterprise viewer – Referrer/clinical distribution – Teleradiology/Remote reading platform. • Addresses ~ 85% of
Slide 12: Milestones - Visage Continued Product Development
Milestones - Visage For personal use only • Continued ongoing Product development • Increased functionality, robustness and scalability • Visage Referrer Access - Visage “Ease” iPad and iPhone “big hits” with referrer base. • Market starting to realise our unique value proposition. • New release (Ve
Slide 13: Milestones – Dual Technology Platform
Milestones – Dual technology platform For personal use only • Two leading edge products – Visage & Coral • Whole greater than the sum of the parts • Unique “4th generation” end to end offering • Dual technology platform basis for future growth
Slide 14: Market Update
For personal use only Annual General Meeting Market Update
Slide 15: Markets - Australia
Markets - Australia For personal use only • Highly consolidated market. • New breakaway opportunities emerging • Early sales of Coral/Visage suite of products encouraging • High demand for Coral from existing clients • Promedicus.net e-health platform to conform to new NEHTA guidelines.
Slide 16: Australian – Management
Australian – Management For personal use only • Danny Tauber – General Manger Australia • Previously Chief Operations Manager • Has been with the company over 19 years. • Positive impact on customer services • Supervising team for Coral roll out in Australia
Slide 17: North America
North America For personal use only • Worlds biggest market. • Visage brand has increasing presence. • Technology edge - thin client, 3D PACS. • Fragmented market - starting to consolidate • Sizeable opportunities for PME • How do we address this market?
Slide 18: US – Management Changes
US – Management Changes For personal use only • Brad Levin – General Manger & Global Head of Marketing • Joined August 2011 • Industry veteran with excellent track record. • Continues to have positive impact in managing the US team. • Success in “spreading the word”.
Slide 19: US – Management Changes
US – Management Changes For personal use only • Bobby Roe – Director of Solutions Architecture and Customer Experience • Joined October 2011 • Wealth of industry experience. • Spearheads technical and customer focused activities. • Having positive impact on customer experience/satisfaction
Slide 20: North America – Market Opportunities
North America – Market Opportunities For personal use only • Key market for Visage technology • Number of sizeable opportunities • Range of market segments - hospitals, remote reading groups (teleradiology) and Imaging Centres • Lengthened decision process due to financial market uncertainty. • Mark
Slide 21: North America – RSNA 2012
North America – RSNA 2012 For personal use only
Slide 22: Europe
Europe For personal use only • Increased emphasis on direct and partner sales channels • Opportunities in 2013 NHS PACS refresh and beyond. • Extended lead times due to economic uncertainties in euro zone. • Needs to be seen as a longer term opportunity
Slide 23: European – Management – Malte Westerhoff
European – Management – Malte Westerhoff For personal use only • Co Founder and co-developer of Visage platform • Leads team of 40 people • Building direct and partner sales capability • Forming platform for future European growth • Instrumental in promoting US sales opportunities
Slide 24: European – Management – Detlev Stalling
European – Management – Detlev Stalling For personal use only • Co Founder and co-developer of Visage platform • Head of Visage R&D • Heads very strong development team • Post Amira– full-time focus on Visage platform
Slide 25: Visage – OEM Business
Visage – OEM Business For personal use only 21 • Visage technology embedded in 3rd party products • Still important in terms of European revenue • Sales in both Europe and US • Key contracts performing well
Slide 26: Market Trends
For personal use only Annual General Meeting Market Trends
Slide 27: Modular approach – Viewer/VNA/Workflow
Modular approach – Viewer/VNA/Workflow For personal use only • Move away from monolithic PACS solutions. • Larger hospitals looking for VNA (Vendor Neutral Archive) plus viewing layer. • Remote Reading/Teleradiology – read anywhere anytime • Imaging Centers – looking for complete solution • Visage t
Slide 28: Pricing Models – Pay per View
Pricing Models – Pay per View For personal use only • Pay per View gaining increasing acceptance. • Alternative to capital model • Already used in recent US and European contracts • Starting to be adopted in Australia • Upside as client examination volumes grow • Revenue spread more evenly over leng
Slide 29: Summary
For personal use only Summary • Successful year of R&D – Visage and Coral • Sale of Amira - increases cash but interim revenue impact • Resumption of dividends • Extremely strong balance sheet
Slide 30: Summary
For personal use only Summary •Two leading edge products – Visage & Coral •Dual technology platform - foundation for growth •New pricing model – pay per view to be greater % of revenue •North American and European markets - significant opportunities
Slide 31: Annual General Meeting November 2012
For personal use only Annual General Meeting November 2012
Slide 32: Resolution of Shareholders – Remuneration Report
RESOLUTION OF SHAREHOLDERS For personal use only • Resolution 2 – To adopt the Remuneration Report (non binding) FOR OPEN AGAINST 79,423,919 262,432 305,195 99.29% 0.33% 0.38%
Slide 33: Resolution of Shareholders – Election of Dr Sam Hupert
RESOLUTION OF SHAREHOLDERS For personal use only • Resolution 3A – To elect as a Dr Sam Hupert FOR OPEN AGAINST 50,127,626 263,932 15,579 99.45% 0.52% 0.03%